Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Analysis of little-explored regions of genome reveals dozens of cancer triggers

By R&D Editors | October 4, 2013

Image: Patrick LynchA massive data analysis of natural genetic variants in humans and variants in cancer tumors has implicated dozens of mutations in the development of breast and prostate cancer, a Yale Univ.-led team has found.

The newly discovered mutations are in regions of DNA that do not code for proteins but instead influence activity of other genes. These areas represent an unexplored world that will allow researchers and doctors to gain new insight into the causes and treatment of cancer, said the scientists.

“This allows us to take a systematic approach to cancer genomics,” said Mark Gerstein, the Albert L. Williams Prof. of Biomedical Informatics and co-senior author of the paper, which appears in Science. “Now we do not need to limit ourselves to the roughly 1% of the genome that codes for proteins but can explore the rest of our DNA.”

The analysis—led by Yale researchers and including scientists from the Wellcome Trust Sanger Institute, Cornell Univ, and other institutions—is a statistical marriage of separate mammoth research projects, each providing groundbreaking insights in our genome, the genetic blueprint of life.

The 1,000 Genomes project is compiling the personal genomes of many individuals. The data help pinpoint regions of DNA that vary little within the population and thus are of crucial importance to human health. The Encyclopedia of DNA Elements (ENCODE) project is working toward cataloguing the function of each location in the human genome.

The team took non-coding DNA elements from ENCODE project and looked for those that are highly conserved in the 1,000 Genomes data. They then contrasted the data with mutations in tumor samples from about 90 patients with breast or prostate cancer. They found dozens in areas of DNA that vary little and therefore are likely to drive tumor progression. They also looked for additional features of the cancer mutations such as their proximity to regulatory-network hubs, which also indicate they may be particularly damaging.

While the research focused on variants of single base pairs, many of conclusions also apply to other, larger forms of genetic variation, the authors say.

The great diversity of variants found proves that massive data projects have direct relevance to cancer in individuals, the authors said.

“Our approach can be directly used in the context of precision medicine,” says Ekta Khurana, an assoc. research scientist in Gerstein’s lab and a first author of the study.

Source: Yale Univ.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE